IOP

IOPtima is a medical technology company specializing in the development of minimally invasive surgical solutions for the treatment of glaucoma. The company's flagship product, the IOPtiMate system, utilizes CO2 laser technology to perform a non-penetrating procedure that reduces intraocular pressure (IOP) by thinning the scleral wall. This approach aims to provide a safer and more effective alternative to traditional penetrating surgeries like trabeculectomy, minimizing the risk of complications such as hypotony or infection. Founded in Israel, IOPtima was acquired by Chengdu Kanghong Pharmaceutical Group in 2017 to expand its global reach in the ophthalmic market.